Inside the 10-year, $1 billion battle for the next critical antibiotic10 min read . Updated: 22 Sep 2016, 09:07 PM IST
Gepotidacin may be GlaxoSmithkline's first truly new antibiotic in 30 years to fight the rise of superbugs that risk killing an extra 10 million people every year by 2050
London: In a cramped lab in rural Pennsylvania, surrounded by technicians in obligatory white lab coats and fume hoods leaking an occasional acrid smell, Neil Pearson holds up a plastic model of a chemical compound that resembles a spidery piece of Lego.
Select your Category